PREVIOUS
How does YOUR COMPOUND COMPARE?
Newsletter # 138
In vivo studies
Before entering costly development stages, compounds must demonstrate efficacy in predictive preclinical models. Neurofit's Pristane-Induced Arthritis (PIA) rat model provides the dynamic range needed to identify meaningful therapeutic effects and differentiate promising candidates from the rest.
Tofacitinib has become one of the most widely used targeted therapies for rheumatoid arthritis. When evaluated in Neurofit's PIA model, this clinically validated benchmark compound produced a clear and robust dose-dependent response, reducing disease burden by up to 91%.
UP TO 91% REDUCTION IN ARTHRITIS DISEASE LOAD
■ Detect partial efficacy across early-stage hits,
■ Demonstrate true dose-response relationships,
■ Differentiate subtle efficacy gaps between competing leads,
■ Support rationale-backed lead selection and dose optimization,
■ Generate investor-ready proof-of-concept data.
■ Small molecules & targeted kinase inhibitors,
■ Biologics & monoclonal antibodies,
■ Novel immunomodulators,
■ First-in-class anti-inflammatory agents.
■ Pristane-Induced Arthritis (PIA),
■ Collagen-Induced Arthritis (CIA,)
■ Oxazolone-Induced Dermatitis,
■ Ovalbumin-Induced Allergic Inflammation.
■ Collagen-Induced Arthritis (CIA,)
■ Oxazolone-Induced Dermatitis,
■ Ovalbumin-Induced Allergic Inflammation.
-
We look forward to hearing from you.
